Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Offers $1.2M in American Depositary Shares

NEW YORK (GenomeWeb) – Australian molecular diagnostics firm Genetic Technologies said on Wednesday that it has entered into a securities purchase agreement with certain institutional investors in the US.

Under the agreement, the investors will purchase approximately 1.5 million American Depositary Shares (ADS), each representing 150 of the company's ordinary shares, at a price of $.80 per ADS.

The company said it will receive gross proceeds of about $1.2 million before deducting customary offering expenses. The investors also agreed to purchase warrants to buy an aggregate of about 1,1 million ADS at an exercise price of $.80 per share. The warrants will be exercised immediately following the date of issuance and will expire five years thereafter.

Melbourne-based Genetic Technologies said it will use the proceeds for general product development and R&D, expansion in China, and to fund the development of polygenic risk tests with TGen in the US.

The company currently markets the GeneType for Breast Cancer and GeneType for Colorectal Cancer risk assessment tests, which use PCR arrays to genotype a number of cancer susceptibility loci.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.